Clinical Overview
Suvorexant is a dual orexin receptor antagonist indicated for insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It represents a novel mechanism for treating insomnia by blocking the wake-promoting orexin system rather than enhancing sleep-promoting systems like traditional hypnotics, potentially offering a more physiological approach to sleep induction.
Primary Clinical Applications
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It may be particularly suitable for patients who want to avoid benzodiazepines or Z-drugs, those concerned about dependence potential, or patients who experience residual effects with other sleep medications.
Mechanism and Clinical Benefits
Suvorexant selectively blocks orexin OX1R and OX2R receptors, which are responsible for promoting wakefulness. By antagonizing these wake-promoting signals, it allows the natural sleep drive to predominate, potentially providing more physiological sleep compared to GABA-enhancing medications.
Clinical Considerations
Suvorexant has a lower risk of tolerance and dependence compared to benzodiazepines and Z-drugs. However, it can cause next-day somnolence and may impair driving ability the morning after use. The medication should be taken with at least 7 hours available for sleep, and dose adjustments are needed for certain patient populations and drug interactions.
Prescribing Information
Dosing & Administration
Insomnia – Adults:
- Recommended dose: 10 mg once nightly
- Maximum: 20 mg once nightly
- Initial dose for some patients: 5 mg once nightly
Dose Modifications:
- Moderate CYP3A inhibitors: Maximum 5 mg nightly
- Strong CYP3A inhibitors: Not recommended
- CNS depressant use: Consider lower dose
Administration:
- Take within 30 minutes of going to bed
- Ensure at least 7 hours available for sleep
- Take only when able to stay in bed for full night
- Do not take with or soon after a meal
Indications
- Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance
Contraindications
- Hypersensitivity to suvorexant
- Narcolepsy
Warnings & Precautions
- CNS depression: Risk increased with alcohol and other CNS depressants
- Next-day impairment: May affect driving ability the morning after use
- Sleep paralysis: Temporary inability to move or speak for up to several minutes
- Hypnagogic/hypnopompic hallucinations: Vivid experiences during sleep-wake transitions
- Cataplexy-like symptoms: Temporary weakness with strong emotions
- Complex sleep behaviors: Activities while not fully awake
- Depression: May worsen depression or suicidal ideation
Drug Interactions
- Strong CYP3A inhibitors: Not recommended (ketoconazole, clarithromycin)
- Moderate CYP3A inhibitors: Reduce suvorexant dose to maximum 5 mg
- CNS depressants: Enhanced sedation, consider dose reduction
- Alcohol: Avoid concurrent use
Adverse Reactions
Common (≥2%):
- Somnolence, headache, dizziness, abnormal dreams
- Dry mouth, cough, upper respiratory tract infection
Unique to orexin antagonists:
- Sleep paralysis, hypnagogic hallucinations
- Cataplexy-like symptoms
Special Populations
- Hepatic Impairment: Severe impairment: not recommended
- Renal Impairment: No dose adjustment needed
- Pregnancy: Category C – use only if benefits outweigh risks
- Sleep time requirement: Must have ≥7 hours available for sleep
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
